Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method

Annals of Surgical Oncology

Volumn 7, Issue 3, 2000, Pages 193-198

  Takenoue, Tomohiro ^a   Nagawa, Hirokazu ^a   Matsuda, Keiji ^a   Fujii, Shin ^a   Nita, Marcelo Eidi ^a   Hatano, Kenji ^a   Kitayama, Joji ^a   Tsuruo, Takashi ^a   Muto, Tetsuichiro ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Colon carcinoma; Immunohistochemistry; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; COLON CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE;

EID: 0033995850     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02523653     Document Type: Article

References (30)

1. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
2. Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 1997;21:748-62.
3. Drake JC, Voeller DM, Allegra CJ, Johnston PG. The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer 1995;71:1145-50.
4. Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987;71:261-5.
5. Peters GJ, van der Wilt CL, van Triest B, Pisanelli GC. Thymidylate synthase and drug resistance. Eur J Cancer 1995;31A: 1299-305.
6. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12:2035-42.
7. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-9.
8. Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997;15:389-400.
9. Kase S, Kubota T, Watanabe M, et al. The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo. Surg Today 1993;23:615-20.
10. Van der Wilt CL, Braakhuis BJ, Pinedo HM, De Jong M, Smid K, Peters GJ. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer 1995; 61:672-8.
11. Pizzorno G, Sun Z, Handschumacher RE. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 1995;49:553-7.
12. Johnston PG, Fisher ET, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-7.
13. Yeh KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998;82:1626-31.
14. Mirjolet JF, Barberi Heyob M, et al. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998;78:62-8.
15. Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995;31A:1306-10.
16. Kornmann M, Link KH, Lenz HJ, et al. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
17. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988;48:5894-900.
18. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6.
19. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998;4:1227-34.
20. Pestalozzi BC, McGinn CJ, Kinsella TJ, et al. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 1995;71:1151-7.
21. Yamachika T, Nakanishi H, Inada K, et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998;82:70-7.
22. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bc1-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
23. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
24. Beck A, Etienne MC, Cheadame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30A:1517-22.
25. Etienne MC, Cheadame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-70.
26. Katona C, Kralovánszky J, Rosta A, et al. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 1998;55:468-74.
27. McLeod HL, Sludden J, Murray GI, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998;77:461-5.
28. McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996;41:425-7.
29. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998;4:325-9.
30. Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998;77:497-500.